SCHEMBL7176019

SCHEMBL7176019

Cc1cc(OCC(C)C)ccc1PC(=O)c1c(Cl)cccc1Cl.[LiH]

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.41
MEN1 O00255 2/20 0.41
PKM P14618 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
MCL1 Q07820 1/20 0.39
FFAR1 O14842 2/20 0.38
MRGPRX4 Q96LA9 1/20 0.38
XDH P47989 1/20 0.38
MAPT P10636 2/20 0.38
ALDH1A1 P00352 2/20 0.38
NR1H4 Q96RI1 2/20 0.37
FOS P01100 1/20 0.36
JUN P05412 1/20 0.36
TP53 P04637 1/20 0.36
SIRT2 Q8IXJ6 1/20 0.36
HTT P42858 1/20 0.36
PDK2 Q15119 1/20 0.36
TRIM24 O15164 1/20 0.36
ABL1 P00519 1/20 0.35
KDM4E B2RXH2 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7184492 0.97 KMT2A (0.39) KMT2AMEN1PKMSMN1; SMN2MCL1
SCHEMBL7175607 0.94 MAPT (0.39) KMT2AMEN1PKMSMN1; SMN2MCL1
SCHEMBL7175998 0.90 XDH (0.39) MCL1FFAR1XDHALDH1A1NR1H4
SCHEMBL7182069 0.88 S1PR1 (0.41) KMT2AMEN1PKMSMN1; SMN2MCL1
SCHEMBL7182327 0.88 FOS (0.41) KMT2AMEN1XDHMAPTALDH1A1
SCHEMBL7181505 0.88 FOS (0.38) KMT2AMEN1PKMSMN1; SMN2FFAR1
SCHEMBL7188792 0.86 MCL1 (0.42) KMT2AMEN1PKMSMN1; SMN2MCL1
SCHEMBL7189092 0.86 XDH (0.39) KMT2AMEN1SMN1; SMN2FFAR1XDH
Lithium SCHEMBL7182340 0.86 FOS (0.39) KMT2AMEN1XDHMAPTALDH1A1
SCHEMBL7177558 0.85 S1PR1 (0.39) KMT2AMEN1PKMSMN1; SMN2MCL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 KMT2A 1586/4885MEN1 2312/4885PKM 3848/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 KMT2A 956/4885MEN1 2263/4885PKM 3933/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.